Alice Gottlieb, MD, PhD of Icahn School of Medicine at Mount Sinai and she is bullish on bermekimab based on her recent presentation at Dermatology and Venereology Congress, noting I neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis that includes a substantial reduction in pruritus.
Sponsored by XBiotech, which TrialSite News interviewed on the weekly podcast as well as wrote about the application of their investigational drug for hidradenitis suppurativa. This recent study a Phase II, open-label study which was scheduled to end December 2018 and involve 38 participants. The multi-center study, it turned out of the 38 patients 10 patients with moderate to severe atopic dermatitis received weekly 200 mg bermekimab subcutaneous injections for 4 weeks while 28 patients received weekly 400 mg bermekimab subcutaneous injections 8 weeks.
Healio reported that disease measures evidenced improvement in the 400 mg group, and notable improvements in clinical outcomes were observed compared to the 200 mg group according to the meeting’s abstract. The study was conducted at Florida Academic Centers Research & Education from Coral Gables, Florida.
Alice Gottlieb Comments to Healio Dermatology
Dermatologists have not been exposed to treatments targeting anti-IL-1 alpha. They need to learn about IL-1 in the skin and what it does.” She continued “They now have a potential new tool in their toolbox to treat diseases like atopic dermatitis and hidradenitis suppurativa with a new class of medications targeting IL-1, which is novel.”
Call to Action: Interested in more details on this study? Trialsite News can take a deeper dive if enough of our HS community members desire this.Source: Healio